Drug reimportation decreases power of FDA's standards

09/6/2013 | Life Science Leader

Laws that validate drug reimportation empowers counterfeit drug activity and motivates lawful foreign-based drugmakers not to comply with FDA standards, Rob Wright writes. Many drugs that U.S. consumers want to reimport are cheaper because they are produced under lesser standards of quality, Wright writes. Patients in the U.S. have peace of mind knowing their prescription drugs are effective and safe, and reimportation would threaten that, according to an open letter from PhRMA President and CEO John J. Castellani that Wright cites.

View Full Article in:

Life Science Leader

Published in Brief: